Particle mixture of rasagiline mesylate as well as preparation method and application of particle mixture

Through the mixed solvent recrystallization method of ethanol and methyl tert-butyl ether, the problem of large particle size and complex process of rasagilan methanesulfonic acid is solved, and the particle size uniformity and mixing uniformity are significantly improved, which is suitable for industrial production , and reduces impurity and isomer content.

CN118993897APending Publication Date: 2024-11-22SUZHONG PHARMACEUTICAL GROUP CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310548058.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-16
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing rasagilan methanesulfonic acid recrystallization has large particle sizes, which is not conducive to the consistency of the formulation and the evaluation of efficacy. The existing process steps are complex and there is a problem of hygroscopicity when the particle size is too small.

Method used

Recrystallization is performed using a mixed solvent of ethanol and methyl tert-butyl ether, and the particle size is controlled to be between 20-200 μm or 20-135 μm. By adjusting the solvent ratio and temperature, crystallization and drying are performed to avoid physical treatment steps.

Benefits of technology

It has achieved a significant improvement in particle size uniformity, a mixing uniformity of ±10%, comply with the pharmacopoeia standards, simplified the process, is suitable for large-scale production, and reduces the impurity and isomer content.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004230348720000011
    Figure HDA0004230348720000011
  • Figure HDA0004230348720000012
    Figure HDA0004230348720000012
  • Figure HDA0004230348720000021
    Figure HDA0004230348720000021
Patent Text Reader

Abstract

The invention belongs to the technical field of medicine preparation, and particularly relates to a particle mixture of rasagiline mesylate as well as a crystallization method and application of the particle mixture. According to the method, ethanol and methyl tert-butyl ether are adopted as solvents to recrystallize rasagiline mesylate, rasagiline mesylate crystals with small particle sizes can be obtained, the particle size range is controlled between 10 microns and 200 microns, and the preparation production requirements are completely met; and the method keeps a high yield and is suitable for large-scale industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of chemical substance preparation, and specifically to a crystallization method of rasagiline mesylate. Background Art

[0002] Parkinson's disease (PD), also known as tremor paralysis, is a common neurodegenerative disease with typical symptoms of resting tremor, muscle rigidity, and bradykinesia. Rasagiline is a second-generation monoamine oxidase inhibitor that can block the decomposition of the neurotransmitter dopamine. Compared with selegiline (a first-generation monoamine oxidase inhibitor, including selegiline, midazolam, and ginsipelan), its inhibitory effect is 5-10 times stronger, and it also has an improvement effect on patients with a decline in the efficacy of long-term use of dopamine preparations. In addition, the metabolite of rasagiline is an inactive non-amphetamine substance with few side effects. More importantly, the drug has a certain symptom relief effect, and there is more evidence that this type of drug has a certain neuroprotective effect. Agilect (rasagiline mesylate) is used alone as a first-line drug for the early treatment of Parkinson's disease (PD) or in combination with levodopa (levodopa) to treat moderate to severe Parkinson's disease.

[0003] The particle size index of particles in drugs is widely valued and recognized by the industry. Particles in tablet mixtures can cause problems for the homogeneous distribution of drugs due to reasons such as size and shape. If such drug substances are used to make tablets without further processing, the tablets produced will lack content uniformity and will not have acceptable drug content. If the amount of drug substance is too high, poor content uniformity may also cause toxicity. And the amount of rasagiline mesylate in the preparation is very low compared to the total weight of the tablet, so small fluctuations in the amount of raw materials lead to considerable content uniformity deviations due to fluidity or separation problems. Drugs are usually measured by weight, but volume also plays an important role in the tablet preparation process. If the crystals of the raw materials form large and irregular shapes, it will significantly affect the content uniformity. And smaller particle size can improve solubility and promote gastrointestinal absorption or oral absorption; particle size may affect the fluidity and mixing of drugs. In the case of good fluidity of the active ingredient, tablets can be prepared by directly compressing the ingredients.

[0004] Patent document CN101123946B indicates the importance of controlling the particle size range of 6 to 250 μm in the process of rasagiline preparation. The crystal D prepared by the grinding method is 90 The value decreased from 389 to 598 μm to 156 to 189 μm. Patent document EP2271612B1 uses a mixed solvent of ethyl acetate and methanol for crystallization to obtain product D 90The value is 1407-1496 μm, and the grinding method is used to obtain particles of less than 300-400 μm. Patent document US20110218360A1 also uses a micronization method to treat the prepared crystals. That is, the existing rasagiline preparation process technology generally uses physical methods such as grinding and micronization to prepare crystals with smaller particle sizes. At the same time, there are many steps, and equipment and processes need to be added in large-scale production. If the particle size after treatment is too small, it needs to be packaged under inert gas due to hygroscopicity. At the same time, the physical treatment process has other risks such as crystal transformation.

[0005] Therefore, it is necessary to provide a method for preparing rasagiline mesylate with a smaller particle size by a recrystallization method. Summary of the invention

[0006] Purpose of the invention: The technical problem to be solved by the present invention is to overcome the defects and shortcomings of the existing rasagiline mesylate recrystallization, that is, the particle size obtained is large, which is not conducive to the subsequent preparation and consistency of drug efficacy evaluation, and to provide a rasagiline mesylate granular mixture with significantly reduced particle size and uniformity.

[0007] The technical problem that the present invention needs to solve is to provide a method for preparing the above-mentioned rasagiline mesylate granule mixture.

[0008] The technical problem that the present invention needs to solve is to provide a composition containing the above-mentioned rasagiline mesylate granule mixture.

[0009] The final technical problem to be solved by the present invention is to provide the application of the above-mentioned rasagiline mesylate granule mixture and the above-mentioned composition.

[0010] In order to solve the above-mentioned first technical problem, the present invention discloses a rasagiline mesylate granular mixture, characterized in that the particle size D 90 In some embodiments, the particle size D 90 In some embodiments, the detection method is light scattering.

[0011] In order to solve the second technical problem, the present invention discloses a method for preparing the rasagiline mesylate granule mixture, comprising the following steps: recrystallizing rasagiline mesylate with a mixed solvent of ethanol and methyl tert-butyl ether.

[0012] In some embodiments, the mass volume ratio of rasagiline mesylate to ethanol is 1:2-8, in some embodiments, 1:3-7, in some embodiments, 1:4-6; the volume ratio of methyl tert-butyl ether to ethanol is 1:0.5-3.5, in some embodiments, 1:1-3, in some embodiments, 1:1.5-2.5; the ethanol in some embodiments is anhydrous ethanol.

[0013] In some embodiments, the ethanol is anhydrous ethanol; in some embodiments, the ethanol is 95% ethanol.

[0014] In some embodiments, the crystallization temperature of the recrystallization is -7 to 15°C, in some embodiments, -6 to 11°C, and in some embodiments, -5 to 10°C.

[0015] In some embodiments, the recrystallization includes heating and dissolving the rasagiline mesylate in ethanol and then adding methyl tert-butyl ether; in some embodiments, the heating temperature is 50-80°C, preferably 55-75°C, and in some embodiments, 60-70°C; in some embodiments, the heating is followed by heat preservation and stirring, and the time of heat preservation and stirring is 0-3h, in some embodiments, 0.5-2.5h, and in some embodiments, 1-2h; the purpose of heat preservation and stirring is to dissolve the rasagiline mesylate, so it is sufficient to ensure that the rasagiline mesylate is dissolved, and heat preservation and stirring may not be required or may be appropriate. In some embodiments, the temperature is lowered after heat preservation and stirring, and in some embodiments, the temperature of the cooling is 10-70°C, in some embodiments, 20-60°C, and in some embodiments, 30-50°C; in some embodiments, methyl tert-butyl ether is added after cooling.

[0016] In some embodiments, after adding methyl tert-butyl ether, the mixture is kept warm with stirring; in some embodiments, the temperature of the keeping warm with stirring is 10-70°C, in some embodiments, 20-60°C, and in some embodiments, 30-50°C; in some embodiments, the keeping warm with stirring time is 0-5h, in some embodiments, 0.5-3.5h, and in some embodiments, 1-3h; in some embodiments, after the keeping warm with stirring, the temperature is lowered, and the mixture is kept warm with stirring for a second time to perform recrystallization; in some embodiments, the second keeping warm with stirring time is 0-3h, preferably 0.5-2.5h, and in some embodiments, 1-2h; in some embodiments, a second keeping warm with stirring is not required.

[0017] In some embodiments, the recrystallization is filtered after crystallization, and the filtering method in some embodiments is suction filtration.

[0018] In some embodiments, the filter cake obtained after filtration is washed with methyl tert-butyl ether; in some embodiments, the mass volume ratio of methyl tert-butyl ether used for washing to rasagiline mesylate is 1:4-17, preferably 1:5-16, and in some embodiments 1:6-15; in some embodiments, the filter cake is dried; in some embodiments, the drying is vacuum drying; in some embodiments, the drying temperature is 20-70°C, preferably 30-60°C, and in some embodiments 40-50°C; in some embodiments, the drying time is 1-4h, in some embodiments 1.5-3.5h, and in some embodiments 2-3h. In some embodiments, washing with methyl tert-butyl ether is not required. In some embodiments, natural drying is used instead of instrument drying.

[0019] In some embodiments, rasagiline mesylate is added with ethanol in a volume ratio of 1:2 to 8 times relative to its mass, heated at 50-80°C with stirring until dissolved and clarified, kept warm with stirring for 0-3 hours, and cooled to 10-70°C; methyl tert-butyl ether is added in a volume ratio of 1:0.5-3.5 relative to ethanol, kept warm with stirring at 10-70°C for 0-5 hours, then cooled to -7-15°C, kept warm with stirring for 0-3 hours, filtered, the filter cake is washed with methyl tert-butyl ether, and the filter cake is vacuum dried at 40-50°C.

[0020] In some embodiments, the stirring speed is 30 to 170 rpm; in some embodiments, 40 to 160 rpm; in some embodiments, 50 to 150 rpm.

[0021] In some embodiments, the rasagiline mesylate particle mixture is prepared by the above preparation method.

[0022] In order to solve the third technical problem mentioned above, the present invention discloses a pharmaceutical composition, which comprises the above-mentioned particle mixture as an active ingredient, and a pharmaceutically acceptable excipient or carrier; in some embodiments, the composition is prepared as an oral preparation.

[0023] In order to solve the fourth technical problem mentioned above, the present invention discloses the use of the above-mentioned particle mixture or the above-mentioned pharmaceutical composition in the preparation of a drug for treating Parkinson's disease; in some embodiments, it is used for preparing a combined treatment for treating primary Parkinson's disease or patients with end-of-dose fluctuations.

[0024] The inventors have found in practice that during the recrystallization process of rasagiline mesylate, a particle mixture with a larger particle size is easily obtained; and the method of the present invention can avoid this problem.

[0025] In some embodiments, the initially added rasagiline mesylate is measured by high performance liquid chromatography. If there are impurity peaks (excluding solvent peaks) in the chromatogram, the single impurity is less than 0.5% and the total impurity is less than 3.5% calculated by normalization of the peak area; in some embodiments, the S-isomer is also less than 3%.

[0026] It has been verified that the premixed content uniformity of the particle mixture within the particle size range of the present invention is significantly better, the content meets ±10% of the labeled amount, and is basically close to the labeled amount; the premixed content uniformity RSD is ≤5.0%, even within 2.1%. The product sample after preparation meets the content within ±5% of the labeled amount.

[0027] The method of the present invention can be used for the purification preparation of rasagiline mesylate. According to the high performance liquid chromatography method, if there are impurity peaks (except the solvent peak) in the chromatogram, the peak area normalization calculation shows that the single impurity shall not exceed 0.1%, the total impurity shall not exceed 1.0%, and the S-isomer shall not exceed 1%.

[0028] The present invention adopts a mixed solvent of ethanol and methyl tert-butyl ether to recrystallize rasagiline mesylate, and the amount of the ignition residue of the obtained product meets the pharmacopoeia standard, while the product obtained by recrystallization using a mixed solvent of isopropanol and methyl tert-butyl ether does not meet the standard; the amount of the ignition residue of the method of the present invention is significantly less than that of the combined recrystallization method using isopropanol and methyl tert-butyl ether. At the same time, the uniformity of the particle size of the product obtained by recrystallization using the method of the present invention is also significantly higher than that of the product obtained by the combined recrystallization of isopropanol and methyl tert-butyl ether.

[0029] The particle mixture of the present invention is an existing form of rasagiline mesylate raw material and has a smaller particle size.

[0030] Beneficial effects:

[0031] The method of the invention adopts ethanol and methyl tert-butyl ether as recrystallization solvents to recrystallize rasagiline mesylate, and can directly obtain rasagiline mesylate crystals with smaller particle size without being treated by a physical method, and the particle size range is controlled to be below 200 or even 135 μm, with high uniformity, which fully meets the production preparation requirements, and has significantly better mixing uniformity. At the same time, the obtained product has less inorganic impurities; and a high yield is maintained, and the method is safe and environmentally friendly, and the process is simplified, which is suitable for large-scale industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 This is a particle size detection report of the rasagiline mesylate product obtained in Example 1 of the present invention.

[0033] Figure 2 This is a particle size detection report of the rasagiline mesylate product obtained in Example 2 of the present invention.

[0034] Figure 3This is a particle size detection report of the rasagiline mesylate product obtained in Example 3 of the present invention. DETAILED DESCRIPTION

[0035] The present invention is further described below with reference to the accompanying drawings and specific embodiments, but the embodiments do not limit the present invention in any form.

[0036] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the present technical field.

[0037] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0038] In the following examples, the rasagiline mesylate used in Examples 1-3 was from the same batch.

[0039] The particle size distribution was measured by a Bettersize 2600 laser particle size analyzer.

[0040] The purity and S-isomer were determined by high performance liquid chromatography (General Chapter 0512 of the Chinese Pharmacopoeia, Part IV, 2020 Edition).

[0041] The temperature in the examples is the reaction liquid temperature.

[0042] Example 1 Preparation of Rasagiline Mesylate Granular Mixture

[0043] In a 20L reactor, 0.39kg of rasagiline mesylate and 1.39kg of anhydrous ethanol were added, heated and stirred at 60°C until dissolved and clarified, stirred for 1h, and cooled to 40°C; 2.89kg of methyl tert-butyl ether was added, stirred at 40°C for 2h, then cooled to 0°C, stirred for 1h, filtered, the filter cake was washed with methyl tert-butyl ether, and the filter cake was vacuum dried at 45°C for 2h to obtain 0.37kg of rasagiline mesylate product, with a yield of 94.87% and a purity of 99.94%. 90 =88.71μm.

[0044] Example 2 Preparation of Rasagiline Mesylate Mixture

[0045] In a 20L reactor, 0.39kg of rasagiline mesylate was added, 6 times the mass volume ratio of ethanol relative to rasagiline mesylate, heated and stirred at 65°C until dissolved and clarified, kept warm and stirred for 2h, and cooled to 50°C; 2.5 times the volume ratio of methyl tert-butyl ether relative to anhydrous ethanol was added, kept warm and stirred at 50°C for 1h, then cooled to 10°C, kept warm and stirred for 2h, filtered, the filter cake was washed with methyl tert-butyl ether, and the filter cake was vacuum dried at 50°C for 3h to obtain 0.36kg of rasagiline mesylate product, with a yield of 92.31% and a purity of 99.94%. 90 =86.92μm.

[0046] Example 3 Preparation of Rasagiline Mesylate Mixture

[0047] In a 20L reactor, 235.6 g of rasagiline mesylate was added, 95% ethanol was 4 times the mass volume ratio of rasagiline mesylate, heated at 70 ° C with stirring until dissolved and clarified, kept warm and stirred for 1 hour, and cooled to 30 ° C; methyl tert-butyl ether was added with a volume ratio of 1.5 times that of anhydrous ethanol, kept warm and stirred for 3 hours at 30 ° C, then cooled to -5 ° C, kept warm and stirred for 1 hour, filtered, the filter cake was washed with methyl tert-butyl ether, and the filter cake was vacuum dried at 40 ° C for 3 hours to obtain 0.36 kg of rasagiline mesylate product, with a yield of 94.62% and a purity of 99.91%. 90 =93.68μm.

[0048] The present invention provides a method and idea for recrystallizing rasagiline mesylate. There are many methods and approaches to realize the technical solution. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the protection scope of the present invention. All components not specified in this embodiment can be implemented by existing technologies.

Claims

1. A granular mixture of rasagiline mesylate, characterized in that: The particle size D 90 It is 10~200μm.

2. The particle mixture according to claim 1, characterized in that The particle size D 90 It is preferably 20 to 135 μm, further preferably 25 to 130 μm, further preferably 30 to 125 μm, further preferably 50 to 120 μm; further, the detection method is a light scattering method.

3. A method for preparing the particle mixture as claimed in claim 1 or 2, characterized in that: The method comprises the following steps: recrystallizing rasagiline mesylate with a mixed solvent of ethanol and methyl tert-butyl ether.

4. The preparation method according to claim 3, characterized in that: The mass volume ratio of rasagiline mesylate to ethanol is 1:2-8, preferably 1:3-7, and more preferably 1:4-6; the volume ratio of methyl tert-butyl ether to ethanol is 1:0.5-3.5, preferably 1:1-3, and more preferably 1:1.5-2.5; the ethanol is preferably anhydrous ethanol.

5. The preparation method according to claim 3, characterized in that: The crystallization temperature of the recrystallization is -7 to 15°C, preferably -6 to 11°C, and more preferably -5 to 10°C.

6. The preparation method according to claim 3, characterized in that: The recrystallization comprises heating and dissolving the rasagiline mesylate in ethanol and then adding methyl tert-butyl ether; preferably, the heating temperature is 50-80°C, preferably 55-75°C, and more preferably 60-70°C; preferably, the heating is followed by heat preservation and stirring, and the heat preservation and stirring time is 0-3h, preferably 0.5-2.5h, and more preferably 1-2h; preferably, the heat preservation and stirring are followed by cooling, and the cooling temperature is preferably 10-70°C, preferably 20-60°C, and more preferably 30-50°C; preferably, methyl tert-butyl ether is added after cooling.

7. The preparation method according to claim 6, characterized in that After adding methyl tert-butyl ether, the mixture is kept warm and stirred; preferably, the temperature of the kept warm and stirred is 10-70°C, preferably 20-60°C, and more preferably 30-50°C; preferably, the kept warm and stirred time is 0-5h, preferably 0.5-3.5h, and more preferably 1-3h; preferably, after the kept warm and stirred, the temperature is lowered, and the mixture is kept warm and stirred for a second time to perform recrystallization crystallization; preferably, the second kept warm and stirred time is 0-3h, preferably 0.5-2.5h, and more preferably 1-2h.

8. The preparation method according to claim 3, characterized in that: The recrystallization is filtered after crystallization, and the filtering method is preferably suction filtration; preferably, the filter cake obtained after filtration is washed with methyl tert-butyl ether; preferably, the mass volume ratio of methyl tert-butyl ether used for washing to rasagiline mesylate is 1:4-17, preferably 1:5-16, and more preferably 1:6-15; preferably, the filter cake is dried; preferably, the drying is vacuum drying; preferably, the drying temperature is 20-70°C, preferably 30-60°C, and more preferably 40-50°C; preferably, the drying time is 1-4h, preferably 1.5-3.5h, and more preferably 2-3h.

9. A pharmaceutical composition, characterized in that A composition comprising the particle mixture according to any one of claims 1 to 10, and a pharmaceutically acceptable excipient or carrier; preferably, the composition is prepared as an oral preparation.

10. Use of the particle mixture according to any one of claims 1, 2 or 8 or the pharmaceutical composition according to claim 9 in the preparation of a medicament for treating Parkinson's disease; preferably, use in the preparation of a combined treatment for treating primary Parkinson's disease or patients with end-of-dose fluctuations.